US HB4553 | 2019-2020 | 116th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on September 27 2019 - 25% progression, died in committee
Action: 2019-09-30 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on September 27 2019 - 25% progression, died in committee
Action: 2019-09-30 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Expands the priority-review voucher program for tropical diseases to include Middle East respiratory syndrome, Nipah virus, and Rift Valley fever. A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Title
Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act
Sponsors
| Rep. Brendan Boyle [D-PA] | Sen. Roger Marshall [R-KS] | Rep. Marc Veasey [D-TX] | Rep. Jeff Fortenberry [R-NE] |
| Rep. Bryan Steil [R-WI] |
History
| Date | Chamber | Action |
|---|---|---|
| 2019-09-30 | House | Referred to the Subcommittee on Health. |
| 2019-09-27 | House | Referred to the House Committee on Energy and Commerce. |
| 2019-09-27 | House | Introduced in House |
Subjects
Cardiovascular and respiratory health
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Infectious and parasitic diseases
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Infectious and parasitic diseases
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/4553/all-info |
| Text | https://www.congress.gov/116/bills/hr4553/BILLS-116hr4553ih.pdf |
